HIGHLIGHTS
- who: Xia Zhang and collaborators from the Harvard Medical School, United States Medical, China, Department of Hepatobiliary Disease, The Third People`s have published the research work: Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation, in the Journal: (JOURNAL)
- how: Data pertaining to the following variables were collected (a) demographic characteristics (b) clinicopathological parameters including BCLC stage the diameter and number of tumors tumor encapsulation immunosuppressive regimen Child-Pugh classification serum AFP level infection with hepatitis B virus cirrhosis complete blood cell counts urine test stool . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.